23 February 2026 Punjab Khabarnama Bureau : Vefa Lifesciences has announced the launch of Neurovorin-15 (Leucovorin Calcium) in India, marking an important addition to its growing specialty pharmaceutical portfolio. The new product is aimed at strengthening supportive care in oncology and other critical therapeutic areas, reflecting the company’s focus on delivering high-quality and affordable medicines to healthcare providers across the country.
Leucovorin Calcium is widely used in clinical practice, particularly as a rescue therapy following high-dose methotrexate treatment and as an adjunct in combination regimens for colorectal and other cancers. It is also prescribed in certain cases to reduce toxicity associated with folate antagonist therapies. With the introduction of Neurovorin-15, Vefa Lifesciences aims to improve access to this essential medicine for hospitals, oncologists, and patients in India.
According to industry experts, the demand for supportive oncology drugs has been steadily increasing due to rising cancer incidence, improved diagnosis, and wider adoption of advanced chemotherapy protocols. The launch of Neurovorin-15 is expected to support clinicians in managing treatment-related side effects more effectively, helping improve patient outcomes and treatment continuity.
Company representatives stated that Neurovorin-15 has been developed and manufactured in compliance with stringent quality standards, ensuring safety, efficacy, and consistency. The product is designed to meet the needs of modern oncology practices, where precision dosing and reliable therapeutic support play a crucial role in patient care.
Vefa Lifesciences has been expanding its footprint in specialized and critical care segments, with a strategic focus on oncology, neurology, and hospital-based therapies. The launch of Neurovorin-15 aligns with the company’s long-term vision to become a trusted partner for healthcare professionals by offering scientifically backed and clinically relevant solutions.
Medical experts note that Leucovorin Calcium continues to be a cornerstone drug in cancer care, particularly in reducing toxicity and enhancing the effectiveness of specific chemotherapy regimens. Its timely availability can be critical in preventing complications and supporting recovery in patients undergoing aggressive cancer treatments.
With this launch, Vefa Lifesciences also aims to strengthen its distribution network across key healthcare markets in India. The company plans to ensure wide availability of Neurovorin-15 through hospital pharmacies, oncology centers, and institutional supply channels, enabling seamless access for clinicians nationwide.
Industry observers view the introduction of Neurovorin-15 as part of a broader trend among Indian pharmaceutical companies to focus on value-added formulations and specialty medicines. As healthcare needs evolve, such launches are seen as vital in supporting India’s growing demand for advanced and reliable therapeutic options.
Vefa Lifesciences reiterated its commitment to innovation, quality, and patient-centric healthcare, stating that the launch of Neurovorin-15 is another step toward addressing unmet medical needs in critical therapy areas. The company is expected to continue expanding its portfolio with similar launches in the coming months.
Summary
Vefa Lifesciences has launched Neurovorin-15 (Leucovorin Calcium) in India, expanding its oncology supportive care portfolio and aiming to improve access to essential medicines for cancer treatment.